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comes in terms of resource use and costs, especially when
withdrawal rates differ between treatment groups. The
aim of this study was to compare the impact of various
methods for dealing with censored data on the total costs
and on the difference in costs between treatment groups.
METHODS: Five methods for dealing with censored
data were applied to data from 519 patients with chronic
disease participating in a one-year randomized clinical
trial. These five methods are complete case analysis, lin-
ear extrapolation, hot-decking, predicted regression, and
multiple imputation.
RESULTS: Fifteen percent of the patients in treatment
group A and 21% of the patients in treatment group B with-
drew from the study before the scheduled end date. Mean
costs per patient varied from €889 (SE: 94) in the complete-
case analysis to €1400 (SE: 189) after predicted regression.
Cost differences between treatment groups varied from €14
in the complete-case analysis, to €243 after multiple impu-
tation, to €372 after predicted regression. Hot-decking,
multiple imputation and predicted regression were sensitive
to the selection of covariates.
CONCLUSION: The various methods had a consider-
able impact on total costs and on the difference in costs
between treatment groups. In economic evaluations more
attention should be paid to methods for dealing with cen-
sored patients and the impact of these different methods
on the CE-ratio.
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OBJECTIVE: An issue that has recently received atten-
tion from health economists is how to handle the prob-
lem of missing data in stochastic cost-effectiveness analy-
sis. The purpose of this paper is to highlight the impact
that different approaches to the imputation of missing
data can have on estimates of the physical quantities of
medical care resource use.
METHODS: Medical care resource use data were col-
lected prospectively in a six-month RCT comparing two
treatments for a chronic condition that is characterized
by acute episodes. Two approaches of the multiple impu-
tation were used to address the problem of missing data.
Method A relied on imputing missing data for total costs
and then estimating the physical quantities of medical
care resource use. Method B relied on imputing missing
data for the physical quantities of medical care resource
use and then estimating total costs. Results for physician
and nurse visits and days in the hospital were reported.
RESULTS: The two multiple-imputation approaches pro-
duced different estimates of medical care resource use.
The average number of physician and nurse visits and
days in the hospital between the two groups were 5.7 vs.
5.3 physician visits, 1.0 vs. 0.9 nurse visits, and 4.0 vs.
4.7 days in the hospital determined with method A. The
average number of physician and nurse visits and days in
the hospital between the two groups were 6.0 vs. 6.3
physician visits, 1.2 vs. 1.3 nurse visits, and 4.0 vs. 5.0
days in the hospital using method B.
CONCLUSIONS: Medical care resource use estimates
are sensitive to the imputation approach. Method B
builds prediction models specifically for the utilization
components under the imputation, and results from the
imputed data sets may be less biased. It also provides
more flexibility for analyzing the cost components.
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OBJECTIVE: The cost of medical procedures is often un-
known, but is nevertheless crucial for setting reimburse-
ment and health-care policies. This study investigated the
cost of an upper gastrointestinal endoscopy in ambula-
tory adults in a large academic hospital in the province of
Québec, Canada from the perspective of the hospital.
METHODS: An activity-based costing methodology was
used to break down the endoscopy procedure into a number
of primary tasks to which were allocated resources used at
the department level (labor, equipment, and materials). Unit
costs per activity were calculated from detailed tracking of
items and factors used for performing each task.
RESULTS: The direct cost of performing an endoscopy
ranged from 62$Can (1Can$  0.75 EUR) for an unse-
dated, unbiopsied patient to 89$Can for a sedated, biop-
sied patient. Not included in this amount are separate re-
imbursement fees of 15$Can for biopsy analysis and
50$Can professional fees for the performing physician,
which are charged directly to the Ministry of Health. A
cost-volume function was constructed under two differ-
ent hypotheses of divisibility (sharing between clinical
units) or undivisibility of fixed equipment. This showed
an optimal unit cost per procedure starting at around
3000 procedures a year for the installed equipment. In-
corporating institutional overhead raises the cost of the
procedure substantially by an amount of 41$ as does the
use of non-reusable biopsy forceps, which adds about
63$Can to the total cost of the procedure.
CONCLUSION: Given the high proportion of overall
hospital-wide overhead in the total cost of the procedure,
allocation methods for these overheads in current hospi-
tal accounting systems should be improved in order to
obtain more precise estimates of the full cost of medical
procedures like upper gastrointestinal endoscopy. The
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use of single-use equipment rather than reusable equip-
ment also increases the variable unit costs significantly.
SESSION II
HEALTH POLICY II
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PRICING OF PHARMACEUTICALS IN CANADA 
AND EUROPE: A COMPARATIVE ANALYSIS
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OBJECTIVES: This paper compares pricing and reim-
bursement of pharmaceuticals between Canada and se-
lected European countries.
METHODS: We examined the pricing and reimburse-
ment schemes and cost-containment initiatives adopted
in Europe and Canada and their impact on prices of ex-
isting and new medications. Published data from the Pat-
ented Medicine Prices Review Board (PMPRB) provides
international price comparisons for patented medicines
available in Canada. Prices for 13 new active substances
first marketed in Canada in 2000 were assembled for
Canada and six European countries. For comparative
purposes, prices in the United States were also included in
the analysis.
RESULTS: Drug prices in Canada are typically lower
than prices in Germany, Sweden, Switzerland, and the
UK but higher than prices in France and Italy. Patented
Drugs were 8% lower than the international median as
measured by the PMPRB. However, for new drugs intro-
duced in 2000, prices were, on average, 8.3% higher than
those in Europe, although most were within the range of
European prices. Prices in Canada and Europe were al-
most always lower than those in the United States.
CONCLUSIONS: The health-care systems in Canada
and Europe are fairly similar, as are the drug pricing and
reimbursement schemes. However, local policies (e.g.,
reference pricing, generic substitution, pharmacoeconom-
ics) can result in significant international price variations
and the potential for parallel importation. Cost-effective-
ness and international price comparisons play an impor-
tant role in most major markets. The prices of pharma-
ceuticals in Canada are comparable to those in Europe
although there is a trend for Canadian prices to be
higher. Although pharmaceutical prices in Canada and
Europe appear to be lower than in the United States,
there are important differences in the health-care systems
as well as in the reimbursement mechanisms that make
price comparisons with the US problematic.
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OBJECTIVE: The System of Objectified Judgement
Analysis (SOJA) method is a recognized, standardized
system, which aims to distinguish a medication of choice
from a class of drugs. It combines expert opinion on pri-
orities during prescription, with clinical evidence per in-
dividual drug. We used the SOJA method in the Irish set-
ting for statins and compared the results to their actual
prescribing patterns in Ireland.
METHODS: A questionnaire was sent to 1,705 Irish gen-
eral practitioners (GPs) asking them to rank between 0
and 10 the relative importance of 11 criteria when pre-
scribing statins. These average results were assigned to
the SOJA method. The higher the overall SOJA score per
medication, the better the statin performed and the more
evidence to support the prescription of this drug over
others in the same class. The SOJA results were com-
pared to the number of statin prescriptions for public pa-
tients at the time the questionnaire was completed (Aug/
Sept 2000).
RESULTS: There was a 42% reply rate. The average or-
der of importance, as rated by the GPs were clinical effi-
cacy (9.26), side effects (8.24), drug interactions (7.93),
dosage frequency (7.53), clinical endpoint studies (7.50),
number of approved indications (7.07), documentation
(6.96), cost-effectiveness (6.95), bioavailablility (6.69),
absorption (6.46) and number of formulations (5.55).
The resulting SOJA score (with number of prescriptions)
were simvastatin 64.6 (7,150), atorvastatin 59.5 (19,770),
pravastatin 59.4 (34,736), cerivastatin 56.3 (3,500) and
fluvastatin 51.4 (4,134).
CONCLUSION: This study indicated that simvastatin
should be the statin of choice in Ireland followed by ator-
vastatin or pravastatin. However, pravastatin is by far
the most widely prescribed statin. This suggests that non-
rationale factors such as marketing may be influencing
prescribing in Ireland. Additionally, despite the fact that
statins represent one of the most expensive long-term
therapies, Irish GPs rank cost-effectiveness low on the list
of priorities during their prescription.
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OBJECTIVE: Our study had two objectives. The first
was to disaggregate historical drug expenditure increases
into three components: price increase, utilization in-
crease, and product shift. The second objective was to
demonstrate the potential impact of pipeline drugs on an-
nual drug-expenditure increases, factoring in what has
been observed historically for newer drugs.
METHODS: The method for calculating pure price infla-
tion involved a fixed set of drugs and measured the utili-
zation-weighted mean of annual percentage increases.
